2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …

N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

An introduction to inverse probability of treatment weighting in observational research

NC Chesnaye, VS Stel, G Tripepi… - Clinical Kidney …, 2022 - academic.oup.com
In this article we introduce the concept of inverse probability of treatment weighting (IPTW)
and describe how this method can be applied to adjust for measured confounding in …

Adherence in hypertension: a review of prevalence, risk factors, impact, and management

M Burnier, BM Egan - Circulation research, 2019 - Am Heart Assoc
The global epidemic of hypertension is largely uncontrolled and hypertension remains the
leading cause of noncommunicable disease deaths worldwide. Suboptimal adherence …

Calciphylaxis

SU Nigwekar, R Thadhani… - New England Journal of …, 2018 - Mass Medical Soc
Calciphylaxis Calciphylaxis is a life-threatening disorder characterized by occlusion of
microvessels in the subcutaneous adipose tissue and dermis. The authors outline the …

Atherosclerosis in chronic kidney disease: more, less, or just different?

JM Valdivielso, D Rodríguez-Puyol… - … , and vascular biology, 2019 - Am Heart Assoc
Patients with chronic kidney disease (CKD) are at an increased risk of premature mortality,
mainly from cardiovascular causes. The association between CKD on hemodialysis and …

[HTML][HTML] Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

AA House, C Wanner, MJ Sarnak, IL Piña… - Kidney international, 2019 - Elsevier
The incidence and prevalence of heart failure (HF) and chronic kidney disease (CKD) are
increasing, and as such a better understanding of the interface between both conditions is …

Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: Synopsis of the kidney disease: improving global outcomes …

M Ketteler, GA Block, P Evenepoel… - Annals of internal …, 2018 - acpjournals.org
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical
Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of …

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

RT Gansevoort, R Correa-Rotter, BR Hemmelgarn… - The Lancet, 2013 - thelancet.com
Since the first description of the association between chronic kidney disease and heart
disease, many epidemiological studies have confirmed and extended this finding. As …

Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal …

C Zoccali, F Mallamaci, M Adamczak… - Cardiovascular …, 2023 - academic.oup.com
Chronic kidney disease (CKD) is classified into five stages with kidney failure being the most
severe stage (stage G5). CKD conveys a high risk for coronary artery disease, heart failure …

Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update

R Vanholder, A Pletinck, E Schepers, G Glorieux - Toxins, 2018 - mdpi.com
In this narrative review, the biological/biochemical impact (toxicity) of a large array of known
individual uremic retention solutes and groups of solutes is summarized. We classified these …